While CNS2 methylation of FOXP3+ suppressive iTreg in breast tumors can efficiently indicate their functional stability and, consequently, their contribution to immune-suppression within the tumor, the small size of obtained clinical samples and technical limitations of DNA methylation analysis at the single-cell level render this approach extremely challenging. The gene discussed is FOXP3; the disease is breast neoplasm.